BC patients harboring hereditary BRCA1/2 mutations respond to treatment with polyadenosine diphosphate ribose polymerase inhibitors, including olaparib, veliparib, talazoparib, and iniparib, and these compounds are other potential options in LC treatment [65]. Here, BRCA1 is linked to breast cancer.